References
- Bastard P, Goffard JC, Emile JF, et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J Exp Med. 2022;219(6):e20220028.
- Bastard P, Orlova E, Soheili-Nezhad S, et al. Autosomal recessive IFNAR1 deficiency with severe COVID-19 pneumonia. J Clin Immunol. 2021;42(1):19–24.
- Chen S, Lee B, Lee AY, Modzelewski AJ, He L. Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes. J Biol Chem. 2016 Nov 25;291(51):14457–14467.
- Diril MK, Esmen K, Sehitogullari T, Öztürk G. Generation of albino C57BL/6J mice by CRISPR embryo editing of the mouse tyrosinase locus. J Genet. 2025;104:7.
- de Weerd NA, Nguyen T. The interferons and their receptors—distribution and regulation. Immunol Cell Biol. 2012;90(5):483–91.
- Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
- Hashimoto M, Yamashita Y, Takemoto T. Electroporation of Cas9 protein/sgRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse. Dev Biol. 2016;418(1):1–9.
- Hernandez N, Megchelenbrink W, Campbell A, et al. Life-threatening MMR vaccine–related infection in an infant with complete IFNAR1 deficiency. J Exp Med. 2019;216(6):1321–1333.
- Khanmohammadi S, Rezaei N, Khazaei M, Shirkani A. A Case of Autosomal Recessive Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency with Severe COVID-19. J Clin Immunol. 2022 Jan;42(1):19-24.
- Kim SR, Lee JM, Kang HJ, Ryou J, Shim SM. Antiviral activity of pimecrolimus against dengue virus type 2 infection in vitro and in vivo. Sci Rep. 2024 Jun 10;14(1):13303.
- Marx V. A rocky road for the maturation of embryo-editing methods. Nat Methods. 2019;16(2):147-150.
- Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology. 2012 Oct 1;1(7):1027-1037.
- Modzelewski AJ, Chen S, Willis BJ, Lloyd KCK, Wood JA, He L. Efficient mouse genome engineering by CRISPR-EZ technology. Nat Protoc. 2018;13(9):1857–76.
- Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918–21.
- Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–86.
- Qin W, Dion SL, Kutny PM, Zhang Y, Cheng AW, Jillette NL, Malagon-Lopez J, Leonetti MD, Corn JE. Efficient CRISPR/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics. 2015 Sep;200(2):423–30.
- Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Schreiber RD. Blocking monoclonal antibodies specific for mouse IFN-α/β receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res. 2006 Nov;26(11):804–19.
- Shepardson KM, Larson K, Johns LL, Stanek K, Cho H, Wellham J, Henderson H, Rynda-Apple A. IFNAR2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections. Front Immunol. 2018 Nov 9;9:2589.
- Schreiber G. The molecular basis for differential type I interferon signaling. J Biol Chem. 2017;292(46):18261–8.
- Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016;16:31–40.
- Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–8.